申请人:PRELUDE THERAPEUTICS INCORPORATED
公开号:US20210346405A1
公开(公告)日:2021-11-11
The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
该披露涉及部分BCL-2抑制剂,包括含有它们的药物组合物,以及它们的使用和制备方法。